Opendata, web and dolomites

EPI-X4Health SIGNED

Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPI-X4Health project word cloud

Explore the words cloud of the EPI-X4Health project. It provides you a very rough idea of what is the project "EPI-X4Health" about.

x4    agents    small    compounds    blood    derivatives    airway    models    deregulation    epi    endogenous    inhibitor    commercialization    pave    named    carcinoma    exists    antagonist    tool    lung    linked    parallel    migration    diseases    cxcl12    mozobiol    antagonists    goals    tolerated    preliminary    approved    efficient    clinical    cxcr4    chemokine    receptor    mouse    model    perform    disorders    inhibits    colon    osteosarcoma    orders    fragment    hiv    magnitude    peptide    screen    occurring    synthetic    mobilizes    asthma    ipr    inflammation    remarkably    preclinical    amd3100    plays    market    progenitor    mice    ligands    arthritis    strategy    stability    potent    plasma    signaling    blocks    coreceptor    inflammatory    identification    safe    modulating    suppresses    cancers    cancer    invasion    hematopoietic    peptidome    rheumatoid    showing    naturally    experimental    serum    treatment    reg    human    dermatitis    stem    libraries    prospects    cell    entry    potency    encompassing    suggest    entire    cardiovascular    allowed    glioblastoma    cells    albumin    chronic    therapeutic   

Project "EPI-X4Health" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET ULM 

Organization address
address: HELMHOLTZSTRASSE 16
city: ULM
postcode: 89081
website: www.uni-ulm.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙156 €
 EC max contribution 149˙156 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET ULM DE (ULM) coordinator 95˙256.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 26˙950.00
3    UNIVERSITE DE STRASBOURG FR (STRASBOURG) participant 26˙950.00

Map

 Project objective

Deregulation of CXCL12 signaling via the CXCR4 chemokine receptor plays a key role in many diseases, including cancer, rheumatoid arthritis, chronic inflammation and cardiovascular disorders. Thus, agents modulating CXCR4 signaling offer many prospects for therapeutic development. CXCR4 is also a major coreceptor for HIV entry. Thus, we used HIV as tool to screen peptide libraries encompassing the entire blood peptidome for novel CXCR4 ligands. This approach allowed the identification of a small fragment of human serum albumin as potent HIV inhibitor. Remarkably, this naturally occurring peptide, named EPI-X4 (Endogenous Peptide Inhibitor of CXCR4), blocks CXCL12/CXCR4 signaling and suppresses cancer cell migration and invasion. Preclinical studies in mice show that EPI-X4 mobilizes hematopoietic stem/progenitor cells and inhibits lung inflammation in an asthma model. Preliminary analyses suggest that EPI-X4 is more specific and better tolerated than Mozobiol® (AMD3100), the only CXCR4 antagonist approved for clinical application. Recently, we developed synthetic derivatives of EPI-X4 showing about three orders of magnitude improved potency against HIV as well as increased plasma stability. Key goals of this project are to determine the therapeutic potential of these improved derivatives against cancers (Aim 1) and inflammatory diseases (Aim 2) using established mouse models of colon carcinoma, osteosarcoma, glioblastoma, airway inflammation and dermatitis. These disorders were selected from the large number of CXCR4-linked diseases because no safe and effective treatment exists and since preclinical mouse models are available to determine whether EPI-X4 derived agents are more efficient and better tolerated than other compounds. In parallel to the experimental assessment of the therapeutic potential of these novel CXCR4 antagonists, we will perform market analyses and develop an IPR strategy to pave the way towards commercialization and future clinical application.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPI-X4HEALTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPI-X4HEALTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

MITOvTOXO (2020)

Understanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell

Read More  

DeCoCt (2019)

Knowledge based design of complex synthetic microbial communities for plant protection

Read More